当前位置: X-MOL首页全球导师 国内导师 › 张楫钦

个人简介

张楫钦,现任华东师范大学青年研究员(紫江优青)、博士生导师、国家优青,长期从事基因编辑与免疫细胞治疗方面的研究工作。近年来致力于利用新型基因编辑技术,探索肿瘤免疫细胞治疗的新方法,开发创新型的肿瘤免疫细胞治疗技术,为肿瘤的临床治疗提供新的解决方案。在国际上首创一种全新的非病毒定点整合CAR-T技术,通过临床前和临床研究证明了其具有出色的安全性和有效性,为解决现有CAR-T领域存在的问题提供了新的技术方法和革命性的解决方案(Nature, 2022)。该研究成果被评为“2022年度中国血液学十大研究进展”、“中国2022年度重要医学进展”。迄今,以第一作者、通讯作者等在Nature、Cancer Cell、Molecular Cancer、Cell Research、Nature Communications等国际知名学术期刊发表SCI论文20多篇。作为课题负责人承担国家自然科学基金3项、国家重点研发计划1项、上海市自然科学基金1项,并参与多项国家及省部级科研项目。 教育经历 2007年9月---2012年6月,华东师范大学,博士 2009年4月---2010年11月,北京生命科学研究所,联合培养 2003年9月---2007年6月,同济大学,本科 工作经历 2022年9月---至今,华东师范大学,研究员 2016年9月---2022年8月,华东师范大学,副研究员 2012年8月---2016年8月,上海市肿瘤研究所,助理研究员 荣誉及奖励 国家自然科学基金优秀青年科学基金项目(2023年) 华东师范大学紫江优秀青年学者(2022年) 2022年度中国血液学十大研究进展,中华医学会血液学分会,2023.1.8,非病毒定点整合CAR-T技术的开发和临床应用 中国2022年度重要医学进展,中国医学科学院,2023.4.16,研发全新一代CAR-T技术提升复发难治性非霍奇金淋巴瘤的治疗缓解率 2022年度科技成果转化贡献奖,南方周末报社,2022.12.8,非病毒定点整合CAR-T技术

研究领域

利用新型基因编辑工具开发新一代CAR-T技术 利用新型筛选方法鉴定提高CAR-T细胞功能的重要蛋白并开发新疗法 利用合成生物学方法开发新一代免疫细胞治疗技术

近期论文

查看导师新发文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

Jiqin Zhang#*, Yongxian Hu#, Jiaxuan Yang#, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature, 2022, 609(7926):369-374. (IF=69.504) Yongxian Hu#, Cheng Zu#, Mingming Zhang#, Guoqing Wei#, Wei Li#, Shan Fu, Ruimin Hong, Linghui Zhou, Wenjun Wu, Jiazhen Cui, Dongrui Wang, Bing Du, Mingyao Liu, Jiqin Zhang*, He Huang*. Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study. eClinicalMedicine, 2023, 60:102010. (IF=17.033) Jiayi Cheng, Mingyao Liu*, Jiqin Zhang*. Intelligent tunable CAR-T cell therapy leads the new trend. Synth Syst Biotechnol, 2023, 8(4):606-609. (IF=4.8) Jiqin Zhang*, Bing Du, Mingyao Liu*. Let's turn the CAR-T cells ON and OFF precisely. Cancer Cell, 2022, 40(11):1264-1266. (IF=38.585) Xinyan Zhang#, Shijie Liu#, Yueqian Wang#, Huiqiong Hu, Liang Li, Yibin Wu, Duo Cao, Yuankun Cai, Jiqin Zhang*, Xueli Zhang*. Interleukin-22 regulates the homeostasis of the intestinal epithelium during inflammation. Int J Mol Med, 2019, 43(4):1657-1668. (IF=5.314) Jiqin Zhang#, Fei Song#, Xiaojing Zhao#, et al. EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer. Mol Cancer, 2017, 16(1):127. (IF=41.444) Yuanhui Jia#, Ting Li#, Xiaojie Huang, Xianghong Xu, Xinyao Zhou, Linyan Jia, Jingping Zhu,Dandan Xie, Kai Wang, Qian Zhou, Liping Jin, Jiqin Zhang*, Tao Duan*. Dysregulated DNA methyltransferase 3A upregulates IGFBP5 to suppress trophoblast cell migration and invasion in preeclampsia. Hypertension, 2017, 69(2):356-366. (IF=9.897) Biao Wang#, Jiqin Zhang#, Fei Song, et al. EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1. Cancer Lett, 2016, 381(2):331-40. (IF=9.756) Qian Zhao#, Jiqin Zhang#, Ruoyu Chen#, et al. Dissecting the precise role of H3K9 methylation in crosstalk with DNA maintenance methylation in mammals. Nat Commun, 2016, 7:12464. (IF=17.694) Fei Song, Min Zhou, Biao Wang, Bizhi Shi, Hua Jiang, Jiqin Zhang*, Zonghai Li*. Weak binding to E3 ubiquitin ligase c-Cbl increases EGFRvA protein stability. FEBS Lett, 2016, 590(9):1345-53. (IF=3.864) Jiqin Zhang#, Qinqin Gao#, Pishun Li, et al. S phase-dependent interaction with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation maintenance. Cell Res, 2011, 21(12):1723-39. (IF=46.297) Wenhua Liang#, Ruirong Yi#, Weifang Wang#, Yiwei Shi, Jiqin Zhang, et al. Enhancing the antitumor immunity of T cells by engineering the lipid-regulatory site of the TCR/CD3 complex. Cancer Immunol Res, 2023, 11(1):93-108. (IF=12.020) Shuming Yin#, Mei Zhang#, Yang Liu#, Xiaoyue Sun, Yuting Guan, Xi Chen, Lei Yang, Yanan Huo, Jing Yang, Xiaohui Zhang, Honghui Han, Jiqin Zhang, et al. Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies. Mol Ther, 2022, S1525-0016(22)00672-4. (IF=12.910) Yuanhui Jia, Han Xie, Jiqin Zhang, et al. Induction of TGF-β receptor I expression in a DNA methylation-independent manner mediated by DNMT3A downregulation is involved in early-onset severe preeclampsia. FASEB J, 2020, 34(10):13224-13238. (IF=5.622) Liang Li#, Qiuhui Duan#, Zhiyang Zeng#, Jindong Zhao, Jiawei Lu, Jialiang Sun, Jiqin Zhang, et al. UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/β-catenin signaling. Int J Cancer, 2020, 147(8):2239-2252. (IF=7.316) Lei Yang#, Xiaohui Zhang#, Liren Wang#, Shuming Yin#, Biyun Zhu, Ling Xie, Qiuhui Duan, Huiqiong Hu, Rui Zheng, Yu Wei, Liangyue Peng, Honghui Han, Jiqin Zhang, et al. Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants. Protein Cell, 2018, 9(9):814-819. (IF=15.328) Yanjiao Shao#, Liren Wang#, Nana Guo, Shengfei Wang, Lei Yang, Yajing Li, Mingsong Wang, Shuming Yin, Honghui Han, Li Zeng, Ludi Zhang, Qiurong Ding, Jiqin Zhang, et al. Cas9-nickase–mediated genome editing corrects hereditary tyrosinemia in rats.J Biol Chem, 2018, 293(18):6883-6892. (IF=5.486) Xiuqi Wu, Bizhi Shi, Jiqin Zhang, et al. A fusion receptor as a safety switch, detection, and purification biomarker for adoptive transferred T cells. Mol Ther, 2017, 25(10):2270-2279. (IF=12.91) Wen Xu, Yanyu Bi, Juan Kong, Jiqin Zhang, et al. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN–glioblastoma in vivo. Oncotarget, 2016, 26;7(17):24752-65. Wen Xu#, Yanyu Bi#, Jiqin Zhang, et al. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12. Oncotarget, 2015, 6(36):38840-53. Hua Jiang#, Qiongna Dong#, Xiaoying Luo, Bizhi Shi, Huamao Wang, Huiping Gao, Juan Kong, Jiqin Zhang, et al. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Cancer Lett, 2014, 342(1):113-20. (IF=9.756) Min Zhou#, Hai Wang#, Keke Zhou#, Xiaoying Luo#, Xiaorong Pan#, Bizhi Shi, Hua Jiang, Jiqin Zhang, et al. A novel EGFR isoform confers increased invasiveness to cancer cells. Cancer Res, 2013, 73(23):7056-67. (IF=13.312) Xiaoli Liu#, Qinqin Gao#, Pishun Li#, Qian Zhao, Jiqin Zhang, et al. UHRF1 targets DNMT1 for DNA methylation through cooperative binding of hemi-methylated DNA and methylated H3K9. Nat Commun, 2013, 4:1563. (IF=17.694) Jing He, Lan Kang, Tong Wu, Jiqin Zhang, et al. An elaborate regulation of mammalian target of rapamycin activity is required for somatic cell reprogramming induced by defined transcription factors. Stem Cells Dev, 2012, 21(14):2630-41. (IF=4.39) Yixuan Wang#, Chenguang Zheng#, Yonghua Jiang, Jiqin Zhang, et al. Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. Cell Res, 2012, 22(4):637-48. (IF=46.297)

学术兼职

中国细胞生物学会细胞与基因治疗分会青年委员 中国生物工程学会青年委员 上海市免疫学会青年委员

推荐链接
down
wechat
bug